×
About 4,226 results

ALLMedicine™ Generalized Tonic-clonic Seizures Center

Research & Reviews  933 results

Unilateral cerebral cortical encephalitis (CCE) with positive anti-MOG antibodies: A ca...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137040
Medicine Nie H, Gao H et. al.

May 20th, 2021 - Nowadays, myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) is regarded as an independent inflammatory demyelinating disease. Here, we report a rare case of unilateral cerebral cortical encephalitis (CCE) with positive ...

Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS ...
https://doi.org/10.1111/epi.16925
Epilepsia Pernici CD, Mensah JA et. al.

May 18th, 2021 - Dravet syndrome (DS) is a rare but catastrophic genetic epilepsy, with 80% of patients carrying a mutation in the SCN1A gene. Currently, no antiseizure drug (ASD) exists that adequately controls seizures. In the clinic, individuals with DS often p...

Functional and structural connective disturbance of the primary and default network in ...
https://doi.org/10.1016/j.eplepsyres.2021.106595
Epilepsy Research; Zhang Y, Huang G et. al.

May 16th, 2021 - The present study aims to investigate the disturbance of functional and structural profiles of patients with generalized tonic-clonic seizures (GTCS). Resting-state fMRI and diffusion tensor imaging (DTI) data was collected from fifty-six patients...

Population pharmacokinetics of oxcarbazepine: a systematic review.
https://doi.org/10.1080/17512433.2021.1917377
Expert Review of Clinical Pharmacology; Chen YT, Wang CY et. al.

Apr 14th, 2021 - Oxcarbazepine is commonly used as first-line treatment for partial and generalized tonic-clonic seizures. Owing to the high pharmacokinetic variability, several population pharmacokinetic models have been developed for oxcarbazepine to explore pot...

Health-related quality of life in pediatric patients with partial onset seizures or pri...
https://doi.org/10.1016/j.yebeh.2021.107938
Epilepsy & Behavior : E&B; Trigg A, Brohan E et. al.

Apr 11th, 2021 - Study 311 (E2007-G000-311; NCT02849626) was a Phase 3, multicenter, open-label single-arm study of adjunctive perampanel oral suspension in pediatric patients (aged 4 to <12 years) with partial-onset seizures (POS) (with/without secondarily genera...

see more →

Guidelines  2 results

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic d...
https://doi.org/10.1212/WNL.0000000000005755
Neurology Kanner AM, Ashman E et. al.

Jun 14th, 2018 - To update the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). The 2004 AAN criteria were used to systematically review literature...

CARNEXIV™ (carbamazepine) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206030s000lbl.pdf

CARNEXIV is indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types

see more →

Drugs  1,115 results see all →

Clinicaltrials.gov  2,095 results

Levetiracetam - levetiracetam tablet, film coated-DIRECT RX
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3b62114-a590-f4db-e053-2995a90a9d30

May 31st, 2021 - 1.1 Partial Onset Seizures Levetiracetam tablet is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic...

Lamotrigine - lamotrigine tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=243a427f-8526-415f-b8d0-6b7f6d39d758

May 27th, 2021 - Lamotrigine tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1) Epilepsy—monotherapy ...

Levetiracetam - levetiracetam injection-Gland Pharma Limited
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa883d9c-c6cd-44ab-a1de-058985e4f97f

May 27th, 2021 - Recent Major Changes Section Dosage and Administration (2.1) 12/2020 Indications & Usage Section  Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral...

Topiramate - topiramate tablet, film coated-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=149d20de-f262-4567-aa97-d4d28a1653cb

May 25th, 2021 - Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1); adjunctive therapy for the treatment of partial-onset seizures,...

Carbamazepine - carbamazepine tablet, extended release-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=127f9488-f074-4352-bc41-0a7d3177a4f3

May 23rd, 2021 - Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizu...

see more →

News  81 results

Little Evidence to Support Treatments for Prevention of Sudden Unexpected Death in Epilepsy
https://www.medscape.com/viewarticle/928854

Apr 16th, 2020 - NEW YORK (Reuters Health) - More research is needed to identify effective interventions aimed at preventing sudden unexpected death in patients with epilepsy (SUDEP), according to an updated Cochrane review. SUDEP occurs with an incidence of 1 to ...

FDA Clears Epilepsy Smartwatch for Use in Children
https://www.staging.medscape.com/viewarticle/907432

Jan 8th, 2019 - The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smartwatch (Empatica Inc) for seizure tracking in children as young as age 6. The Embrace smartwatch detects patterns in motion and physiological signals that may be a...

FDA Clears Epilepsy Smartwatch for Use in Children
https://www.medscape.com/viewarticle/907432

Jan 8th, 2019 - The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smartwatch (Empatica Inc) for seizure tracking in children as young as age 6. The Embrace smartwatch detects patterns in motion and physiological signals that may be a...

SUDEP risk may change over time
https://www.mdedge.com/jcomjournal/article/189912/epilepsy-seizures/sudep-risk-may-change-over-time?channel=53
Erik Greb

Nov 27th, 2018 - NEW ORLEANS – Risk for sudden unexpected death in epilepsy (SUDEP) may change over time and yearly patient risk assessments are advisable, based on study results presented at the annual meeting of the American Epilepsy Society. Based on 3 years of.

FDA Expands Use of Epilepsy Drug Perampanel (Fycompa) to Younger Children
https://www.medscape.com/viewarticle/902760

Sep 30th, 2018 - The US Food and Drug Administration (FDA) has granted expanded approval of perampanel (Fycompa, Esai Inc) for the treatment of "partial-onset seizures (POS) with or without secondary generalized seizures" in patients as young as 4 years, the manuf...

see more →